Trial Profile

An Open-Label, Multi-Center, Phase I Study to Evaluate the Safety, Tolerability Pharmacokinetic/Pharmacodynamics and Anti-tumor Activity of Tetra-specific Antibody GNC-039 in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Aug 2026 Planned primary completion date changed from 1 Dec 2025 to 1 Dec 2026.
29 Sep 2025 Planned number of patients changed from 147 to 60.
29 Sep 2025 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com